Standard BioTools Inc (NAS:LAB)

$ 2.4 -0.01 (-0.41%) Market Cap: 909.27 Mil Enterprise Value: 892.58 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 70/100

Q4 2023 Standard BioTools Inc Earnings Call Transcript
Feb 28, 2024

$2.37 (+1.28%)

Earnings
Q3 2023 Standard BioTools Inc Earnings Call Transcript
Nov 07, 2023

$1.99 (-2.45%)

Earnings
Standard BioTools Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
Aug 16, 2023
Q2 2023 Standard BioTools Inc Earnings Call Transcript
Aug 08, 2023

$2.38 (-0.83%)

Earnings
Standard BioTools Inc at Jefferies Healthcare Conference Transcript
Jun 08, 2023
Q1 2023 Standard BioTools Inc Earnings Call Transcript
May 09, 2023

$1.6 (-3.33%)

Earnings
Standard BioTools Inc at KeyBanc Capital Markets Life Sciences & MedTech Investor Forum (Virtual) Transcript
Mar 21, 2023
Standard BioTools Inc at Cowen Health Care Conference Transcript
Mar 08, 2023
Q4 2022 Standard BioTools Inc Earnings Call Transcript
Feb 14, 2023

$2.07 (-1.43%)

Earnings
Q3 2022 Standard BioTools Inc Earnings Call Transcript
Nov 08, 2022

$0.9804 (-2.93%)

Earnings
Q2 2022 Standard BioTools Inc Earnings Call Transcript
Aug 08, 2022

$2.04 (+7.94%)

Earnings
Q1 2022 Standard BioTools Inc Earnings Call Transcript
May 05, 2022

$3.01 (-3.83%)

Earnings
Fluidigm Corp at Piper Sandler Healthcare Conference (Virtual) Pre-recorded Transcript
Nov 22, 2021
Q3 2021 Fluidigm Corp Earnings Call Transcript
Nov 08, 2021

$4.82 (-1.23%)

Earnings
Fluidigm Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 28, 2021
Q2 2021 Fluidigm Corp Earnings Call Transcript
Aug 05, 2021

$6.83 (-0.58%)

Earnings
Fluidigm Corp at Jefferies Healthcare Conference (Virtual) Transcript
Jun 02, 2021
Fluidigm Corp at UBS Global Healthcare Virtual Conference Transcript
May 25, 2021
Fluidigm Corp Virtual Mass Cytometry Investor Day Transcript
May 24, 2021
Q1 2021 Fluidigm Corp Earnings Call Transcript
May 06, 2021

$4.59 (-5.94%)

Earnings
Fluidigm Corp at BTIG Virtual MedTech, Digital Health, Life Sciences, and Diagnostic Tools Conference Transcript
Feb 18, 2021
Q4 2020 Fluidigm Corp Earnings Call Transcript
Feb 10, 2021

$7.09 (+1.58%)

Earnings
Fluidigm Corp at Piper Sandler Healthcare Conference (Virtual) - Pre-recorded Fireside Chat Transcript
Nov 24, 2020
Fluidigm Corp at Stifel Virtual Healthcare Conference Transcript
Nov 17, 2020
Q3 2020 Fluidigm Corp Earnings Call Transcript
Nov 05, 2020

$6.8 (+2.10%)

Earnings
Fluidigm Corp at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Q2 2020 Fluidigm Corp Earnings Call Transcript
Aug 06, 2020

$6.79 (-8.56%)

Earnings
Fluidigm Corp at Jefferies Healthcare Conference (Virtual) Transcript
Jun 03, 2020
Fluidigm Corp at UBS Global Healthcare Conference (Virtual) Transcript
May 19, 2020
Q1 2020 Fluidigm Corp Earnings Call Transcript
May 07, 2020

$4.32 (+18.68%)

Earnings
Fluidigm Corp at Barclays Global Healthcare Conference Transcript
Mar 11, 2020
Fluidigm Corp at Cowen HealthCare Conference Transcript
Mar 03, 2020
Q4 2019 Fluidigm Corp Earnings Call Transcript
Feb 10, 2020

$3.71 (-2.11%)

Earnings
Fluidigm Corp at Piper Jaffray Healthcare Conference Transcript
Dec 04, 2019
Q3 2019 Fluidigm Corp Earnings Call Transcript
Nov 05, 2019

$5.11 (-0.20%)

Earnings
Fluidigm Corp at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Q2 2019 Fluidigm Corp Earnings Call Transcript
Aug 01, 2019

$12.15 (+3.40%)

Earnings
Fluidigm Corp at Jefferies Healthcare Conference Transcript
Jun 04, 2019
Fluidigm Corp at UBS Global Healthcare Conference Transcript
May 21, 2019
Q1 2019 Fluidigm Corp Earnings Call Transcript
May 02, 2019

$13.69 (+3.17%)

Earnings
Fluidigm Corp at Cowen Health Care Conference Transcript
Mar 12, 2019
Q4 2018 Fluidigm Corp Earnings Call Transcript
Feb 07, 2019

$8.55 (+0.94%)

Earnings

Q2 2023 Standard BioTools Inc Earnings Call Transcript

Aug 08, 2023 / 09:00PM GMT

Release Date Price: $2.38 (-0.83%)

Transcript 10-Q8-K

Operator

Hello, and welcome to the Standard BioTools Inc. Second Quarter 2023 Financial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Scott Greenstone, Vice President, Investor Relations and Business Development. Thank you. Mr. Greenstone, you may now begin.

Scott Greenstone

Thank you, operator, and good afternoon, everyone. Welcome to the Standard BioTools' Second Quarter 2023 Earnings Conference Call.

At the close of market today, Standard BioTools released its financial results for the quarter ended June 30, 2023. During this call, we will review our results and provide commentary on our financial and operating performance, market trends and strategic initiatives.

Presenting for Standard BioTools today will be Michael Egholm, Chief Executive Officer and President; and Jeff Black, Chief Financial Officer.

During the call, we may make forward-looking statements about events and circumstances that have not yet occurred, including plans and

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.